• James A Bourgeois, Alan K Koike, Jamie E Simmons, Sarah Telles, and Christopher Eggleston.
• Department of Psychiatry, University of California, Davis, Sacramento, CA 95817, USA. james.bourgeois@ucdmc.ucdavis.edu
• J Neuropsychiatry Clin Neurosci. 2005 Jan 1; 17 (2): 232-8.

AbstractThe authors present six cases in which valproate was used in patients seen by a consultation-liaison service (CLS) to manage delirium and/or psychotic agitation. The intravenous (IV) preparation (Depacon, Abbott Laboratories) was used in two nothing by mouth (NPO) patients, while the liquid oral preparation (Depakene, Abbott Laboratories) was used via nasogastric tube (NGT) in the other patients. All of these cases had suboptimal responses and/or concerning side effects from conventional therapy with benzodiazepines and/or antipsychotics. In all six cases, the CLS use of valproic acid combined with conventional antidelirium medications resulted in improved control of behavioral symptoms without significant side effects from valproic acid. Consultation-liaison psychiatrists should consider the addition of valproic acid to control behavioral symptoms of delirium when conventional therapy is inadequate. This may be especially advisable when problematic side effects result from more conventional psychopharmacological management. Specifically, intravenous valproate sodium may be a viable option for NPO patients.

37 keywords...

hide…